Ozempic and Wegovy have Semaglutide as the active agent. Semaglutide is a synthetic GLP-1 molecule that is modified to bind reversibly with albumin. This allows the slow release of these products. These drugs are also modified to escape the rapid inactivation by DPP4. Ozempic is approved for the management of type II diabetes mellitus and protection against cardiovascular events like death, stroke, and heart attacks in diabetic patients with cardiac comorbidities. Wegovy is approved for weight loss in obese and overweight individuals and also approved for protection against cardiovascular events like death, stroke, and heart attack in obese or overweight individuals with cardiovascular comorbidities.

Semaglutide helps regulate blood glucose, slows gastric emptying, produces the feeling of satiety, and acts on area postrema in medulla oblongata to cause nausea.

Objectives of this talk are:
1. What are incretins?
2. What is GLP-1?
3. What are Semaglutides?
4. Approval for Ozempic and Wegovy.
5. Blood glucose regulation by Semaglutides.
5. Slow gastric emptying (ileal brake) by Semaglutides.
6. Effects of Semaglutides on the brain tissue to produce satiety and nausea.
7. Dosage of Semaglutide for glucose regulation vs. weight loss.
8. Blackbox warning.
9. Side effects.
10. Explanation of the side effects.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight | FDA
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or

Ozempic for weight loss: Does it work, and what do experts recommend?
https://health.ucdavis.edu/blog/cultivating-health/ozempic-for-weight-loss-does-it-work-and-what-do-experts-recommend/2023/07


Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity - PubMed
https://pubmed.ncbi.nlm.nih.gov/36511825/

The metabolic role of vagal afferent innervation | Nature Reviews Gastroenterology & Hepatology
https://www.nature.com/articles/s41575-018-0062-1

Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow | American Journal of Physiology-Gastrointestinal and Liver Physiology
https://journals.physiology.org/doi/full/10.1152/ajpgi.1998.275.5.G984

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Gastroenterology | JAMA | JAMA Network
https://jamanetwork.com/journals/jama/fullarticle/2810542


Wegovy® Pen Instructions | Wegovy® (semaglutide) Injection 2.4 mg
https://www.wegovy.com/taking-wegovy/how-to-use-the-wegovy-pen.html

Wegovy: Uses, Side Effects and Weight Loss
https://www.drugwatch.com/drugs/wegovy/#:~:text=Wegovy%20carries%20a%20black%20box,same%20effects%20occur%20in%20humans.


Why Ozempic Causes Diarrhea and How to Manage Your Symptoms - GoodRx
https://www.goodrx.com/ozempic/diarrhea

Incretin - Wikipedia
https://en.wikipedia.org/wiki/Incretin

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533252/

What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell? - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218725/

Enteroendocrine cell - Wikipedia
https://en.wikipedia.org/wiki/Enteroendocrine_cell#:~:text=in%20the%20duodenum.-,L%20cell,in%20the%20duodenum%20and%20jejunum.

What is ilial brake?
inslag.indd
https://scholarlypublications.universiteitleiden.nl/access/item%3A2956466/view